key: cord-0863741-nhimic3g
authors: Tsapepas, Demetra; Paget, Kathryn; Mohan, Sumit; Cohen, David J.; Husain, S. Ali
title: Clinically Significant COVID-19 Following SARS-CoV-2 Vaccination in Kidney Transplant Recipients
date: 2021-05-18
journal: Am J Kidney Dis
DOI: 10.1053/j.ajkd.2021.05.004
sha: 913eaa7523279933b8d4d3158e69b92cf028ebf5
doc_id: 863741
cord_uid: nhimic3g

nan

Vaccination against SARS-CoV-2 represents an important path toward ending the COVID-19 pandemic and alleviating the severity of COVID-19 in most patient populations. 1, 2, 3 Solid organ transplant recipients are a vulnerable population with significant COVID-19-associated morbidity and mortality. 4, 5 Initial reports indicate an impaired anti-SARS-CoV-2 antibody response among transplant recipients following mRNA vaccination, likely because of maintenance immunosuppression. 6, 7, 8, 9 Whether kidney transplant recipients have low levels of virus-neutralizing antibody not detected by these assays or protective anti-SARS-CoV-2 T-cell immunity is currently unknown, and the critical question is whether the impaired antibody response corresponds to disease susceptibility. Here, we document 13 cases of COVD-19 in previously vaccinated kidney transplant recipients. The Columbia University Institutional Review Board approved this study with a complete waiver of informed consent prior to its conduct. Cases are summarized in Table 1 . Patients who developed COVID-19 after partial vaccination did so 6-29 days after initial vaccination, whereas those who had completed the vaccine series developed COVID-19 1-46 days after vaccination. Time after transplantation varied from 1-18 years. Seven patients had diabetes and all but one had hypertension. Only one patient each was not taking a calcineurin inhibitor or mycophenolate. Presenting symptoms were typical: eight patients (62%) reported fatigue/malaise, six (46%) gastrointestinal symptoms, five (38%) cough, four (31%) fever, three (23%) dyspnea, and three (23%) headache. Three patients had a negative anti-SARS-CoV-2-S IgG test. One patient with a detectable anti-SARS-CoV-2-S IgG test was asymptomatic, antibody testing was performed after COVID-19 diagnosis.

While 10 cases were successfully managed as outpatients, three (0.3% of all vaccinated patients) required hospitalization. One patient required a four-day hospitalization for management of dyspnea and hypoxia (requiring 2L nasal canula). Another patient presented to the hospital six days after receiving the first vaccine dose with weakness and gastrointestinal symptoms and subsequently had a >30-day hospitalization for management of acute pancreatitis and hypoxic respiratory failure, both attributed to COVID-19, requiring a non-rebreather mask for three days and ICU care for four days. The final hospitalized patient initially presented with hypotension and a fall which was deemed related to concomitant infection with a urinary tract infection and COVID-19. The patient developed severe COVID-J o u r n a l P r e -p r o o f 19, including septic shock, acute kidney injury, and hypoxic respiratory failure requiring mechanical ventilation, before dying five days after admission.

Initial SARS-CoV-2 vaccine trials demonstrated great efficacy in the prevention of severe COVID-19, with an incidence of 0.04%-0.08% following completion of the primary vaccination series. [1] [2] [3] Our data indicate a 0.8% incidence of breakthrough COVID-19 and 1.4% overall incidence of COVID-19 following any vaccination in a short follow-up period. Unlike the breakthrough cases observed in general population trials, our cases include patients who developed severe COVID-19 requiring hospitalization and mechanical ventilation. These cases suggest reduced SARS-CoV-2 vaccine efficacy in this vulnerable patient population, likely stemming from the use of maintenance immunosuppression. Our number of cases is too small to draw any conclusions about patient characteristics contributing to the likelihood of COVID-19 following vaccination. The potential for severe COVID-19 despite vaccination is a concern among transplant recipients, and these cases supplement recent reports that most transplant recipients do not develop a measurable antibody response to standard anti-SARS-CoV-2 mRNA vaccination schedules, although immunogenicity is higher once both doses are administered. 6, 7, 8, 9 It is important to recognize that the efficacy of vaccination without the presence of detectable antibodies is unclear at present, as is the degree of protection afforded by the presence of a detectable anti-spike antibody response. Results from this single-center summary must be reviewed with consideration to the dynamic changes of COVID-19 infections, in the context of community disease transmission and vaccination rates. For example, high vaccination rates in the community may benefit transplant recipients by reducing the likelihood of disease exposure and infection even if the vaccines do not confer a robust protective response to the immunosuppressed recipient. Patients should be educated on the importance of vaccination but also on the need to continue to remain vigilant and exercise caution and diligence with public health measures of mask-wearing, social distancing, and hand washing even after vaccination 11 . Additionally, clinicians should continue to consider COVID-19 in the list of differential diagnoses for symptomatic transplant recipients even after COVID-19 vaccination. These findings underscore the urgent need to implement trials for the development of alternate effective vaccine dosing schedules for these patients.

Authors' Contributions: Research area and study design: DT, KP, SM, DJC, SAH; Data acquisition: DT, KP, Data analysis and interpretation: DT, SM, SAH; Supervision or mentorship: SM, DJC. Each author contributed important intellectual content during manuscript drafting or revision and agrees to be personally accountable for the individual's own contributions and to ensure that questions pertaining to the accuracy or integrity of any portion of the work, even one in which the author was not directly involved, are appropriately investigated and resolved, including with documentation in the literature if appropriate. Support: SAH is supported by the National Center for Advancing Translational Sciences (KL2 TR001874). Funders did not have a role in study design, data collection, analysis, reporting, or the decision to submit for publication. Financial Disclosure: The authors declare that they have no relevant financial interests.

Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates

Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine

Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine

COVID-19 in solid organ transplant: A multi-center cohort study

Early description of coronavirus 2019 disease in kidney transplant recipients in New York

Immunogenicity of a Single Dose of SARS-CoV-2

Messenger RNA Vaccine in Solid Organ Transplant Recipients

Weak anti-SARS-CoV-2 antibody response after the first injection of an mRNA COVID-19 vaccine in kidney transplant recipients

Post-vaccine anti-SARS-CoV-2 spike protein antibody development in kidney transplants recipients

Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients

American Society of Transplantation. Statement on COVID-19 vaccination in solid organ transplant recipients

J o u r n a l P r e -p r o o f Peer Review: Received Apr 23, 2021. Evaluated by 2 external peer reviewers, with direct editorial input from a Statistics/Methods Editor, an Associate Editor, and the Editor-in-Chief. Accepted in revised form May 12, 2021.

J o u r n a l P r e -p r o o f